Financhill
Sell
32

PGEN Quote, Financials, Valuation and Earnings

Last price:
$3.61
Seasonality move :
14.07%
Day range:
$3.60 - $3.85
52-week range:
$0.65 - $5.23
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
169.81x
P/B ratio:
30.42x
Volume:
3.1M
Avg. volume:
4.1M
1-year change:
365.72%
Market cap:
$1.3B
Revenue:
$3.9M
EPS (TTM):
-$1.40

Analysts' Opinion

  • Consensus Rating
    Precigen, Inc. has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $8.50, Precigen, Inc. has an estimated upside of 136.11% from its current price of $3.60.
  • Price Target Downside
    According to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $3.60.

Fair Value

  • According to the consensus of 2 analysts, Precigen, Inc. has 136.11% upside to fair value with a price target of $8.50 per share.

PGEN vs. S&P 500

  • Over the past 5 trading days, Precigen, Inc. has underperformed the S&P 500 by -6.3% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Precigen, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Precigen, Inc. has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Precigen, Inc. reported revenues of $2.9M.

Earnings Growth

  • Precigen, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Precigen, Inc. reported earnings per share of -$1.06.
Enterprise value:
1.3B
EV / Invested capital:
--
Price / LTM sales:
169.81x
EV / EBIT:
--
EV / Revenue:
198.26x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-16.54x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$640K
Return On Assets:
-195.32%
Net Income Margin (TTM):
-3912.92%
Return On Equity:
-711.28%
Return On Invested Capital:
-420.48%
Operating Margin:
-1180.05%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue $6.8M $4M $6.3M $953K $2.9M
Gross Profit -$2.9M -$4M $640K -$374K $1.6M
Operating Income -$87.3M -$95.4M -$107.7M -$21.3M -$34.5M
EBITDA -$80.6M -$89.9M -$104.9M -$20.6M -$33.7M
Diluted EPS -$0.37 -$0.55 -$1.40 -$0.09 -$1.06
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $153.1M $162.8M $93M $34.5M $129.6M
Total Assets $376.9M $259.2M $190.7M $83.5M $171.3M
Current Liabilities $29M $104.9M $32.9M $21.2M $32.1M
Total Liabilities $245.7M $116.7M $43M $28.1M $129.4M
Total Equity $131.2M $142.5M $147.7M $55.4M $41.9M
Total Debt $193.3M $90M $6.2M $4.8M $97.1M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations -$66.6M -$75.7M -$72.6M -$22.7M -$29.1M
Cash From Investing -$5M $57.9M -$106.8M $5.7M -$63.4M
Cash From Financing -$9.7M $32.2M $169M $32.1M $93M
Free Cash Flow -$67.1M -$84.3M -$75.6M -$23.6M -$29.5M
PGEN
Sector
Market Cap
$1.3B
$28.5M
Price % of 52-Week High
68.9%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-8.33%
-1.33%
1-Year Price Total Return
365.72%
-20.32%
Beta (5-Year)
1.162
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $3.66
200-day SMA
Buy
Level $2.48
Bollinger Bands (100)
Buy
Level 2.45 - 4.37
Chaikin Money Flow
Buy
Level 9.7M
20-day SMA
Sell
Level $3.97
Relative Strength Index (RSI14)
Sell
Level 43.61
ADX Line
Sell
Level 19.25
Williams %R
Buy
Level -89.7436
50-day SMA
Sell
Level $3.80
MACD (12, 26)
Sell
Level 0.00
25-day Aroon Oscillator
Sell
Level -44
On Balance Volume
Sell
Level -4.3M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-18.7397)
Sell
CA Score (Annual)
Level (-2.7627)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (5.5976)
Buy
Piotroski F Score (Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Stock Forecast FAQ

In the current month, PGEN has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The PGEN average analyst price target in the past 3 months is $8.50.

  • Where Will Precigen, Inc. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Precigen, Inc. share price will rise to $8.50 per share over the next 12 months.

  • What Do Analysts Say About Precigen, Inc.?

    Analysts are divided on their view about Precigen, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Precigen, Inc. is a Sell and believe this share price will drop from its current level to $8.00.

  • What Is Precigen, Inc.'s Price Target?

    The price target for Precigen, Inc. over the next 1-year time period is forecast to be $8.50 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.

  • Is PGEN A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Precigen, Inc. is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.

  • How Can I Buy Shares Of PGEN?

    You can purchase shares of Precigen, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Precigen, Inc. shares.

  • What Is The Precigen, Inc. Share Price Today?

    Precigen, Inc. was last trading at $3.61 per share. This represents the most recent stock quote for Precigen, Inc.. Yesterday, Precigen, Inc. closed at $3.60 per share.

  • How To Buy Precigen, Inc. Stock Online?

    In order to purchase Precigen, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Robinhood Win AI Investing?
Will Robinhood Win AI Investing?

Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…

Is Amazon an AI Stock?
Is Amazon an AI Stock?

With the market starting to look skittish on pure-play AI…

Google Vs NVIDIA Stock: Which Is Best?
Google Vs NVIDIA Stock: Which Is Best?

Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $4.4T
P/E Ratio: 62x

Buy
56
Is AAPL Stock a Buy?

Market Cap: $4.1T
P/E Ratio: 37x

Buy
81
Is GOOG Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 40x

Alerts

Buy
56
SMX alert for Dec 6

SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.

Buy
62
PRAX alert for Dec 6

Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.

Sell
13
PSN alert for Dec 6

Parsons Corp. [PSN] is down 21.1% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock